RxDoctor Payments DataLook up a doctor →

Jessica Levin, NP

Nurse Practitioner · Saint Peters, MONPI 1952898348

Payments from drug & device makers

$9,852in general payments, 2019–2025

Across 474 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Sanofi$799
  • Boehringer Ingelheim$673
  • Johnson & Johnson$561
  • AbbVie$499
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$9,70899%
  • Education$1441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,852 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$6,070
Medicare patients
64
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter165$115,585
Breo ElliptaFluticasone/Vilanterol48$22,910
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$18,990
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$17,125
Spiriva RespimatTiotropium Bromide16$8,297
SymbicortBudesonide/Formoterol Fumarate18$4,680
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$3,487
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,292
Albuterol Sulfate HfaAlbuterol Sulfate132$2,534
Wixela InhubFluticasone Propion/Salmeterol12$1,804
Mometasone Furoate11$924
Fluticasone Propionate42$570
Montelukast Sodium17$118
Pantoprazole Sodium13$68
Prednisone15$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,150$155,620243 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,618$23,67047 claims
Boehringer IngelheimSpiriva Respimat$673$8,29716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →